Kala Bio (KALA) Return on Sales (2019 - 2022)

Kala Bio (KALA) posted Return on Sales of 0.22% for Q4 2022, up 40.51% sequentially from 0.38% in Q3 2022, and up 4.0% YoY from 0.21% in Q4 2021.

Kala Bio (KALA) Return on Sales (2019 - 2022) Analysis & Trends

Kala Bio has reported Return on Sales for 4 years, with the latest figure at 0.22% in Q4 2022.

Quarterly Return on Sales rose 4.0% year-over-year to 0.22% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.22% (down 10.0% YoY) and the FY2022 annual result came in at 0.52%, down 29.0% from the prior year.
Return on Sales improved to 0.22% in Q4 2022 per KALA's latest filing, from 0.38% in the prior quarter.
Over five years, Return on Sales peaked at 0.09% in Q3 2021 and troughed at 0.74% in Q2 2020.
A 4-year average of 0.22% and a median of 0.18% in 2019 frame the typical range for Return on Sales.
The sharpest annual moves came in 2020 and 2021: Return on Sales tumbled 59 bps in 2020, then soared 64 bps in 2021.
Over 4 years, Return on Sales stood at 0.18% in 2019, then advanced by 22 bps to 0.14% in 2020, then plunged by 85 bps to 0.26% in 2021, then gained by 15 bps to 0.22% in 2022.
According to Business Quant data, Return on Sales over the past three periods registered 0.22%, 0.38%, and 0.13% for Q4 2022, Q3 2022, and Q2 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	0.00%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	Kala Bio	9.87 Mn	9.87 Mn	-	-

Download Data